Tesofensine – Comprehensive Research Overview (2026)
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, dopamine, and norepinephrine) originally developed for Parkinson’s and Alzheimer’s disease, where it was found to produce significant weight loss as a side effect. It is now primarily researched as an anti-obesity agent. Tesofensine produces appetite suppression and increased energy expenditure through central nervous system mechanisms distinct from GLP-1 agonists, making it a complementary option in metabolic research.
→ View Tesofensine (for laboratory research use only)
Mechanism of Action
- Inhibits presynaptic reuptake of serotonin, dopamine, and norepinephrine, increasing their synaptic availability.
- Reduces appetite and food intake via central monoaminergic pathways.
- Increases resting metabolic rate and energy expenditure.
- May activate cholinergic pathways contributing to additional metabolic effects.
Clinical Evidence and Research Findings
Phase 2 trials (TIPO-1) demonstrated weight loss of 6.5–12.8% over 24 weeks depending on dose, significantly outperforming placebo. Phase 3 trials have been conducted in select markets. Tesofensine shows particular promise in combination with metoprolol (to mitigate cardiovascular side effects) and is being explored alongside GLP-1 agonists for additive effects.
→ Interested in researching Tesofensine? View Product Options
Benefits (Research & Clinical Observations)
- Significant weight loss via central appetite suppression
- Increased energy expenditure and resting metabolic rate
- Complementary mechanism to GLP-1 agonists
- Oral once-daily dosing
- Potential cognitive benefits (original CNS indication)
Typical Dosing Protocols (Research / Clinical Trials)
- Clinical trial doses: 0.25–0.5 mg orally once daily
- Often combined with metoprolol 50 mg to reduce heart rate elevation
- Cycles: 12–24 weeks in trials
Safety Profile and Side Effects
Common side effects: Dry mouth, nausea, constipation, insomnia, increased heart rate and blood pressure (dose-dependent). Cardiovascular monitoring is important.
Monitoring recommended: Heart rate, blood pressure, mood/psychiatric symptoms, metabolic markers. Contraindicated with MAOIs or in uncontrolled hypertension.
Tesofensine vs Semaglutide vs Phentermine – Quick Comparison
| Aspect | Tesofensine | Semaglutide | Phentermine |
|---|---|---|---|
| Mechanism | Triple monoamine reuptake inhibitor | GLP-1 receptor agonist | Norepinephrine releaser |
| Weight Loss | ~10–13% (Phase 2) | ~15% | ~5–8% |
| FDA Status | Not approved (US) | Approved | Approved (short-term) |
Summary
Tesofensine is a potent triple monoamine reuptake inhibitor with compelling Phase 2 weight-loss data and a unique CNS-based mechanism complementary to GLP-1 agonists. Its oral convenience and distinct pathway make it an interesting research tool in metabolic and obesity science. As with all compounds in this library, Tesofensine is not FDA-approved and should only be considered under qualified medical supervision with cardiovascular monitoring.
For Laboratory Research Use View Tesofensine →
Disclaimer This overview is strictly educational and based on publicly available scientific literature and regulatory information as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.